The primary objective of this study was to assess the efficacy and safety of different doses of rhNGF when administered as eye drops to patients with Dry Eye.
Dry Eye Syndrome
Safety and Tolerability after ascending or descending dose
Biological: Recombinant Human nerve growth factor 20 µg/mL
Biological: Recombinant Recombinant Human nerve growth factor 4 µg/mL or 60 µg/mL
Mar 2014 - Group1
Oct 2014 - Group2
Group 1: 20 patients (rh-NGF 20 µg/mL)
Group 2: 20 patients (rh-NGF 4 or 60 µg/mL)
Copyright 2017 © Dompé farmaceutici S.p.A. All rights reserved.
Dompè does not assume any responsibility for the contents